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Sarcoidosis is a systemic granulomatous disease of unknown etiology. NOD2 mutations have been shown to predispose to granulomatous
diseases, including Crohn's disease, Blau syndrome, and early-onset sarcoidosis, but not to adult sarcoidosis. We found that intracellular
Propionibacterium acnes, a possible causative agent of sarcoidosis, activated NF-κB in both NOD1- and NOD2-dependent manners. Systematic
search for NOD1 gene polymorphisms in Japanese sarcoidosis patients identified two alleles, 796G-haplotype (156C, 483C, 796G, 1722G) and
796A-haplotype (156G, 483T, 796A, 1722A). Allelic discrimination of 73 sarcoidosis patients and 215 healthy individuals showed that the
frequency of 796A-type allele was significantly higher in sarcoidosis patients and the ORs were significantly elevated in NOD1-796G/A and
796A/A genotypes (OR [95% CI]=2.250 [1.084, 4.670] and 3.243 [1.402, 7.502], respectively) as compared to G/G genotype, showing an
increasing trend across the 3 genotypes (P=0.006 for trend). A similar association was found when 52 interstitial pneumonia patients were used as
disease controls. Functional studies showed that the NOD1 796A-allele was associated with reduced expression leading to diminished NF-κB
activation in response to intracellular P. acnes. The results indicate that impaired recognition of intracellular P. acnes through NOD1 affects the
susceptibility to sarcoidosis in the Japanese population.
© 2006 Elsevier B.V. All rights reserved.Keywords: NOD2; TLR2; Granulomatous disease; NF-κB1. Introduction
Sarcoidosis, a disease of unknown etiology, may result from
exposure of genetically susceptible subjects to a specific
environmental agent(s), possibly an infectious one. Polymorph-
isms of several genes including those encoding the vitamin D
receptor [1], CC chemokine receptor [2], RANTES chemokine⁎ Corresponding author. Fax: +81 3 5803 0123.
E-mail address: eishi.path@tmd.ac.jp (Y. Eishi).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.07.006promoter [3], tumor necrosis factor-beta [4], and IL-18 [5] have
been reported to be involved in the susceptibility or disease
severity of sarcoidosis.
Propionibacterium acnes is so far the only bacterium to be
isolated from sarcoid lesions. Genomes of P. acnes have been
detected in large numbers of sarcoid lymph nodes by the
quantitative polymerase chain reaction [6,7]. By hybridization
in situ, P. acnes DNA was found in sarcoid granulomas [8].
These results point to an etiological link between P. acnes and
some cases of sarcoidosis.
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recruitment domain, a centrally located nucleotide-binding
oligomerization domain (NOD), and a domain consisting of
multiple leucine-rich repeats [9]. NOD1 acts as a pattern
recognition receptor for bacterial peptidoglycan containing
diaminopimelic acid (iE-DAP) [10]. The iE-DAP structure is
present in a subset of bacteria that include Gram-negative
bacilli and certain Gram-positive bacteria such as Listeria
monocytogenes [10]. Activation of NOD1 induces NF-κB
activation with subsequent inflammatory cytokine production
[11]. Recent studies have revealed that certain NOD1
polymorphisms are associated with asthma, elevated IgE, and
inflammatory bowel disease [12,13].
Mutations in the related NOD2 gene have been shown to
predispose to granulomatous diseases including Crohn's disease
[14], Blau syndrome [15], and early-onset sarcoidosis [16].
Although Blau syndrome and early-onset sarcoidosis were
reported to share identical NOD2 mutations, no association has
been reported between NOD2 and sarcoidosis [17].
Because NOD1 shares many structural and functional
similarities with NOD2, the aim of this study was to investigate
the role of NOD1 polymorphisms in determining susceptibility
to sarcoidosis, in connection with the ability of NOD1 to
recognize intracellular P. acnes which is a possible causative
agent of this disease.
2. Materials and methods
2.1. Study subjects and DNA extraction
Study subjects included 73 patients with biopsy-proven sarcoidosis, 215
healthy control subjects, and 52 patients with interstitial pneumonia as disease
control subjects. The diagnosis was made at the Japanese Red Cross Medical
Center. Samples from healthy control subjects were obtained at the health care
division of the medical center; samples from people with normal test results
were selected. Written informed consent was obtained from all subjects before
starting the study, and the ethics committee of the medical center approved the
study. Genomic DNAwas extracted from peripheral blood from all subjects with
QIAamp DNA mini kit (QIAGEN Inc., Valencia, CA, USA) according to the
manufacturer's instruction.
2.2. Detection of NOD1 polymorphism in sarcoidosis patients
The 11 exons of the NOD1 gene were screened by direct sequencing of DNA
from 50 patients with sarcoidosis. PCR for exon amplification was performed in
50 μl of a mixture containing 3 μl of a DNA sample, 5 pmol of each primer in a
previous report [18], 10 nmol of each of the four deoxynucleotides, 100 nmol of
MgCl2, 1.25 U of Ex Taq, and Ex Taq buffer (1×) (TAKARA Shuzo, Shiga,
Japan) to make 50 μl. Amplification was performed with GeneAmp PCR System
9700 (Applied Biosystems, Foster City, CA, USA) with a profile of 95 °C for
5 min and 35 cycles of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 1 min.
Synthesis of appropriately sized PCR products was confirmed by agarose gel
electrophoresis, and PCR products were purified using the DNA Fragment
Purification Kit (TOYOBO, Osaka, Japan), according to the manufacturer's
protocol. Purified DNA products were sequenced using an ABI PRIME BigDye
Terminator Cycle sequencing kit version 3.1 (Applied Biosystems). Primers for
the PCR amplification were used as sequence primers. Fragments were analyzed
using the ABI PRISM 3100 GENETIC ANALYZER automated DNA
sequencing machine (Applied Biosystems). Sequencing data were compared
with the published NOD1 sequence (GenBank accession number NM 006092)
using BLAST2 sequences software obtained from the website of the National
Center for Biotechnology Information (Bethesda, MD; http://www.ncbi.nlm.
nih.gov/blast/bl2seq/wblast2.cgi).2.3. Genotyping
Genotyping of the NOD1 single nucleotide polymorphism was carried out
using a Custom TaqMan® 5′ allelic discrimination assay (Applied Biosystems).
Each PCR reaction was carried out using 15 ng of DNA in 25 μl reaction
mixture containing 12.5 μl of TaqMan Universal PCRMaster mix (2×) (Applied
Biosystems), 0.625 μl of AssayMix (40×) (Applied Biosystems) and 6.875 μl of
dH2O per sample. Primers and TaqMan® probe for this analysis were designed
and synthesized by Custom TaqMan® SNP Genotyping assay service (Applied
Biosystems). Probes were labeled with VIC or 6-FAM on the 5′-terminal for
detecting G-residue or A-residue, respectively, on 796 base-position of NOD1
mRNA. These primers and probes were contained in Assay Mix (40×) with
optimal concentration. Thermal cycle conditions were as follows: 95 °C for
5 min and 40 cycles of 92 °C for 15 s and 60 °C for 1 min. All PCR and endpoint
fluorescent readings were performed on an ABI PRISM 7900 HT Sequence
Detection System (Applied Biosystems). Samples detected with only VIC or
6-FAM signal were judged as 796G/G or 796A/A genotype, respectively.
Samples detected with both signals were judged as 796G/A genotype. These
results were in complete agreement with the data obtained from the preceding
direct sequencing of the genes in 50 patients with sarcoidosis and thus
confirmed the reliability of our genotyping method.
2.4. Infection protocol and NF-κB activation assay
P. acnes strains were grown in Gifu-anaerobic-medium broth (Nissui
Pharmaceutical Co., Ltd., Tokyo, Japan) at 37 °C under anaerobic conditions for
3 days before use.
HEK293T cells grown to 80% confluence in 12-well plates in DMEM
supplemented with 10% fetal calf serum were transfected by the Ca-phosphate
method with reporter plasmids (7.3 ng pBxIV-luc and 73 ng pEF-BOS-β-gal/
well) and together with pcDNA3-NOD1-FLAG (0.15, 0.3 and 0.6 ng/well),
pcDNA3-NOD2 (0.01 ng/well), or pFLAG-CMV1-TLR2 (1.0 ng/well). Eight
hours after the transfection, HEK293T cells were infected with bacteria at a
multiplicity of infection of 100, or incubated with the respective ligand; iE-DAP
(100 ng/ml) for NOD1, muramyldipeptide (10 ng/ml) for NOD2, and
N-palmitoyl-S-(2,3-bis[palmitoyloxy]-[2RS]-propyl)-(R)-cysteine-CSK4
(Pam3-CSK4) (10 ng/ml) for TLR2. After incubation for 6 h at 37 °C,
extracellular bacteria were removed by washing and the cells were incubated
with DMEM containing 300 μg/ml of gentamicin to kill the remaining
extracellular bacteria until the luciferase activity assay. To assess the effects by
invasiveness of the P. acnes strains, bacteria were passively internalized into the
cells by the Ca-phosphate transfection method as used in plasmid transfection.
Twenty-four hours after transfection of reporter genes, luciferase activity was
determined. Results were normalized for transfection efficiency with values
obtained with pEF-BOS-β-gal.
Construction of the plasmids pcDNA3-NOD1-FLAG and pcDNA3-NOD2
has been previously described [9,19]. The plasmid expressing TLR2 was
generously provided by Dr. R. Medzhitov (University of Yale). iE-DAP was
synthesized as described previously [10]. Synthetic muramyldipeptide was pur-
chased from Peptide Institute, Inc. (Osaka, Japan) and Pam3-CSK4was purchased
from Invitrogen (Carlsbad, CA, USA).
796A-NOD1 was generated using QuikChange Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA, USA) and used for the NF-κB activation assay
described above as well as for protein expression assay. To compare the protein
expression level, HEK293T cells were transfected with 30 ng or 60 ng of either
p796G-NOD1-FLAG or p796A-NOD1-FLAG together with 30 ng of plasmid
encoding aMyc-tagged control protein. Twenty-four hours after transfection, the
cells were lysed in 0.2% Nonidet P-40 lysis buffer and resolved by 10% SDS-
PAGE. The expressed protein was detected by immunoblotting with anti-FLAG
(Sigma-Aldrich, Tokyo, Japan) and anti-Myc (Roche, Tokyo, Japan) mono-
clonal antibodies.
2.5. Statistical analysis
Statistical comparisons were performed using SAS version 9.1 (SAS
institute, Cary, NC, USA). χ2 tests and ANOVA were used to compare
qualitative and quantitative variables between groups, respectively, followed by
Bonferroni correction for multiple comparisons. Student's t-test was used to
796 T. Tanabe et al. / Biochimica et Biophysica Acta 1762 (2006) 794–801compare the luciferase activity indices of two NOD1 variants for each stimulant.
A P-value less than 0.05 was considered significant. Odds ratios (ORs) and
confidence intervals (CIs) were calculated with the use of a logistic regression
model.3. Results
3.1. P. acnes strains isolated from sarcoidosis patients invade
epithelial cells
We initially studied a P. acnes strain isolated in our
laboratory from a subcutaneous lesion of a 25-year-old
woman with sarcoidosis and a type strain of P. acnes (ATCC
6919). No difference was found between the clinical strain and
the type strain by the bacteriological method or by polymerase
chain reaction with 16 s rRNA. Notably, infection of epithelial
cell lines (A549 and HEK293T) with the clinical strain led to
localization of the bacteria inside the cells whereas that with the
type strain did not (Fig. 1). We then examined the cellular
localization of other P. acnes strains isolated from sarcoid
lymph nodes and found strains with invasive phenotype
localized intracellularly and strains with non-invasive pheno-
type localized extracellularly. Ten strains of P. acnes including
five with invasive and five with non-invasive phenotypes were
used to determine intracellular recognition as described below.
3.2. Recognition of intracellular P. acnes by NOD1 and NOD2
We performed overexpression assays in HEK293T cells to
explore a possible function of NOD proteins in host recognition
of P. acnes. HEK293T cells were selected to facilitate the
analysis of bacterial recognition because they are highly
transfectable and lack endogenous Toll-like receptors. Infection
of HEK293T cells with the clinical strain of P. acnes enhanced
the reporter gene activity in NOD1-, NOD2-, and TLR2-
transfected cells (Fig. 2A), indicating that both TLR2 and NOD
family proteins can activate NF-κB in response to P. acnes. In
contrast, NOD1- and NOD2-dependent NF-κB activation by
the type strain of P. acnes was not detectable, indicating the
importance of intracellular invasiveness of P. acnes for NODFig. 1. Invasiveness of P. acnes into epithelial cells. A549 cells were infected with a c
extracellular bacteria were removed by washing and by incubation for 2 h with DMEM
Intracellular P. acnes was found by Giemsa stain in only the clinical strain.signaling. Both strains of P. acnes activated NF-κB in a TLR2-
dependent manner. Notably, NOD1 and NOD2 conferred
responsiveness to the type strain after passive internalization
of the bacteria into the cells (Fig. 2B). To confirm these results,
we examined NOD1 responses to ten additional P. acnes
isolates from sarcoid lymph nodes including five with invasive
and five with non-invasive phenotypes (Fig. 2C). Although all
five invasive isolates activated NOD1, all five non-invasive
isolates stimulated NOD1 only after passive internalization.
Taken together,these data indicate that NOD1 and NOD2 are
involved in the recognition of intracellular P. acnes.
3.3. NOD1 polymorphism and genotyping
We carried out a systematic search for the presence of
polymorphic variants by the direct sequencing of the 11 exons
of NOD1 from 50 sarcoidosis patients (Table 1). Analysis
revealed one nucleotide change in exon 1 (156C>G) and four in
exon 3 (483C>T, 796G>A, 1722G>A, 2108C>A) (Table 1).
Two (796G>A and 2108C>A) of the five detected NOD1
variants resulted in changed amino acid residues (E266K and
P703Q) located in the nucleotide-binding domain and the
leucine-rich repeat domain, respectively. As the 2108C>A
variant was observed only monoallelically in a single patient,
subsequent studies focused on the other four NOD1 variants.
Because all of the four nucleotide polymorphisms occurred
together without exception, the NOD1 alleles were classified
into two haplotypes, 796G-haplotype (156C, 483C, 796G,
1722G) and 796A-haplotype (156G, 483T, 796A, 1722A).
Genotype results in 73 patients with sarcoidosis, 52 patients
with interstitial pneumonia, and 215 healthy subjects are
shown in Tables 2 and 3. A comparison of the sarcoidosis and
healthy control groups showed that the ORs were significantly
elevated in both NOD1-796G/A and 796A/A genotypes (OR
[95% CI]=2.250 [1.084, 4.670] and 3.243 [1.402, 7.502],
respectively) as compared to G/G genotype, showing an
increasing trend across the 3 genotypes (OR per +1 allele
[95% CI]=1.769 [1.182, 2.647], P=0.006). A similar
association was found in the analysis using interstitial
pneumonia patients as disease controls although some resultslinical strain (A) or a type strain (B) of P. acnes. After incubation for 6 h at 37 °C,
containing 300 µg/ml of gentamicin to kill the remaining extracellular bacteria.
Fig. 2. NOD1 and NOD2 mediate NF-κB activation by intracellular P. acnes. HEK293T cells were transiently transfected with reporter genes alone (control), or
together with NOD1, NOD2, or TLR2 expression plasmids. A. The transfected cells were incubated in the absence (□) or presence of each ligand ( ), or infected with
the clinical strain (▪) or the type strain ( ) of P. acnes. B. NOD1, NOD2 and TLR2 stimulation by P. acnes strains or microbial ligands passively internalized intoHEK293T cells by the Ca-phosphate transfection method. C. NOD1 response to ten additional isolates of P. acnes. HEK293T cells were incubated with (□) or
passively internalized with ( ) each isolate. The NOD1-transfected HEK293T cells were also incubated with (▪) or passively internalized with ( ) each isolate.Control means absence of stimulator and ligand means iE-DAP. 1 to 5 represent invasive P. acnes strains and 6 to 10 non-invasive strains. Values represent the mean of
normalized data ± SD of triplicate cultures.
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seen between disease controls and healthy controls (data not
shown).
Frequencies of 796G- and 796A-haplotypes are summarized
in Table 4. A comparison of data obtained from sarcoidosis
patients and both healthy and disease controls showed that the
796A-type allele was also associated with sarcoidosis (OR
[95% CI]=1.681 [1.151, 2.454] and 1.747 [1.051, 2.904],
respectively).Table 1
Sequence variations of NOD1 gene in 50 Japanese patients with sarcoidosis
Location Nucleotide
change
Amino acid
change
Protein
domain
Allele
frequency
Heterozygous/
homozygous
Exon 1 156 C>Ga – CARD 0.55 25/15
Exon 3 483 C>Ta – – 0.55 25/15
Exon 3 796 G>Aa E266K NOD 0.55 25/15
Exon 3 1722 G>Aa – – 0.55 25/15
Exon 3 2108 C>A P703Q LRR 0.01 1/0
CARD, caspase activation and recruitment domain; NOD, nucleotide-binding
oligomerization domain; LRR, leucine-rich repeat domain.
a These four mutations occurred together forming two haplotypes in all cases
analyzed.3.4. Recognition of intracellular P. acnes by the 796A-NOD1
variant
To examine whether 796G>A change affects the expression
and/or function of the NOD1 gene, we constructed a NOD1
cDNA containing the G796A substitution and compared the
expressed protein level of the two variants by immunoblotting.
The analysis revealed that transfection of the NOD1 cDNA
bearing 796A results in reduced expression in comparison with
cDNA bearing 796G (Fig. 3A). By densitometric analysis, the
expression of 796A-NOD1 was found to be decreased by
approximately 50% compared to that of 796G-NOD1 (Fig. 3A,
top). Control experiments showed that the reduced level ofTable 2
Genotype frequencies of NOD1 polymorphism in sarcoidosis and controls
Group n The number (%) of each genotype
G/G G/A A/A
Sarcoidosis 73 11 (15) 42 (58) 20 (27)
Interstitial pneumonia 52 14 (27) 32 (62) 6 (12)
Healthy individuals 215 66 (31) 112 (52) 37 (17)
Table 3
Results of logistic regression analysis for the association of NOD1 genotype
with sarcoidosis
Genotype Odds ratio (95% CI) for sarcoidosis
vs. healthy control vs. disease control
Dominant model
G/G 1 1
G/A or A/A 2.497 (1.235, 5.046), P=0.011 2.077 (0.855, 5.041), P=0.106
Recessive model
G/G or G/A 1 1
A/A 1.816 (0.973, 3.391), P=0.061 2.893 (1.071, 7.818), P=0.036
Per allele
G/G 1 1
G/A 2.250 (1.084, 4.670) 1.670 (0.670, 4.166)
A/A 3.243 (1.402, 7.502) 4.242 (1.269, 14.179)
Per allele 1.769 (1.182, 2.647), P=0.006 2.027 (1.122, 3.661), P=0.019
CI, confidence interval.
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efficiency, because co-transfection with a plasmid encoding a
control Myc-tagged protein showed similar levels of expression
for 796G and A (Fig. 3A, bottom).
We then evaluated the functional difference of 796A- and
796G-NOD1 by analyzing the NF-κB activity in response to iE-
DAP in HEK293T cells transfected with various amounts of the
vectors encoding the two variants. Consistent with reduced
expression of the NOD1 protein, the ability of 796A-NOD1 to
activate NF-κB was reduced by approximately 50% compared
with that of 796G-NOD1 (Fig. 3B). The activity of 796A-
NOD1 produced by transfection with 0.3 ng or 0.15 ng of the
expression vector were almost comparable with that of 796G-
NOD1 transfected with 0.15 ng and 0.3 ng of expression vector,
respectively. In response to intracellular P. acnes, the 796A-
NOD1 variant exhibited reduced ability to activate NF-κB
compared with 796G-NOD1 (Fig. 3C). Thus, the reduced
activity of the 796A-NOD1 variant in response to iE-DAP and
P. acnes can be explained by reduced expression of the NOD1
protein.
4. Discussion
In the presented study, we examined the role of NOD1 and
NOD2 proteins in host recognition of P. acnes and the
association of NOD1 polymorphisms with sarcoidosis. We
show for the first time that both NOD proteins recognize
intracellular P. acnes and that the 796A-NOD1 variant thatTable 4
Haplotype frequencies of NOD1 polymorphism in sarcoidosis and controls
CI, confidence interval.exhibits impaired response to P. acnes is associated with
sarcoidosis. These findings warrant further studies on NOD1
polymorphisms to clarify the functional effects of NOD1
variants and their relevance in the context of sarcoidosis.
It is well accepted that sarcoidosis arises through a
combination of genetic and environmental factors, and Th1
polarization and persistent accumulation of inflammatory cells
are regarded as pathophysiologic characteristics. We previously
reported the involvement of P. acnes in the etiology of
sarcoidosis by showing the accumulation of P. acnes genomes
in sarcoid granulomas [6–8]. The Kveim test phenomenon
implicates that host factors play an important role in sarcoidosis.
Recombinant trigger-factor protein from P. acnes has been
reported to cause a cellular immune response in some patients
with sarcoidosis, but not in subjects without sarcoidosis [20]. P.
acnes trigger factor protein has also been shown to cause
pulmonary granulomas in mice sensitized with the protein and
adjuvant [21]. Especially considering that P. acnes is the most
common commensal bacterium in the lungs and mediastinal
lymph nodes [22,23], local proliferation of this endogenous
bacterium may trigger sarcoid granulomatous inflammation in
genetically predisposed individuals [24].
We have shown in the present study that the clinical isolate of
invasive P. acnes stimulates NOD1 and NOD2 as well as TLR2,
suggesting a possible association between pathogenicity and
NOD response. P. acnes has been studied for its role in
immunomodulation with the conclusion that TLR2, TLR4 and
TLR9 mediated the effects of P. acnes infection [25,26].
However, these studies were only concerned with non-invasive
P. acnes. TLRs are likely to serve as the first line receptors for P.
acnes, but NOD proteins might play a major role in a
subsequent phase of intracellular infection.
As we have shown in this study, both invasive and non-
invasive P. acnes can be isolated from sarcoid lymph nodes.
This difference in invasiveness and the subsequent response by
NOD proteins might explain, at least in part, the previously
reported diversity of the clinical isolates of P. acnes in their
ability to modulate the antimicrobial peptide and chemokine
expression [27].
Although the exact mechanism that regulates the invasive-
ness of P. acnes has not been determined, a recent report has
demonstrated a critical dependency on the interaction of bound
fibronectin with integrins and involvement of TGF-β1 in the
cellular invasion of Group A Streptococcus [28]. Further studies
are needed to examine the involvement of these factors in the
invasion of P. acnes and their role in the pathogenesis of
sarcoidosis.
Fig. 3. Reduced expression and impaired response to P. acnes of the 796A-
NOD1 variant. A. HEK293T cells were transfected with 0, 30, or 60 ng of
either 796G-NOD1 or 796A-NOD1 together with 30 ng of control plasmid
encoding. Myc-tagged protein. The cell lysates were separated by 10% SDS–
PAGE, and immunoblotted with anti-FLAG or anti-Myc antibody. Representa-
tive results are shown. B. HEK293T cells were transiently transfected with
reporter genes alone (control), or together with 0.15, 0.3, or 0.6 ng of either
796G- or 796A-NOD1 expression plasmid. The transfected cells were incubated
in the absence (□) or presence of iE-DAP (▪). C. HEK293T cells weretransiently transfected with reporter genes alone (control), or together with
796G- or 796A-NOD1 expression plasmid. The transfected cells were incubated
in the absence (□) or presence of iE-DAP ( ), or infected with the clinical strain
(▪) or the type strain ( ) of P. acnes. Values represent the mean of normalizeddata ± SD of triplicate cultures.
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but the present study has identified genetic variation in NOD1
that is associated with sarcoidosis. The two NOD proteins have
distinctive distribution patterns. NOD1 is widely distributed [9],
whereas the expression of NOD2 is mainly restricted to
monocytes and macrophages [19]. In a series of studies [29],
we found intracellular P. acnes not only in the lymphoid tissues(lymph nodes, spleen, etc.) but also in many parenchymal organs
including the lungs, liver, heart, skeletal muscles, and kidneys.
Whereas, in the lymphoid tissues, P. acnes infects macrophages
or dendritic cells which express both NOD1 and NOD2, in
parenchymal organs, the bacterium infects non-phagocytic
parenchymal cells which express NOD1 but not NOD2. These
observations lead us to speculate that the difference in tissue
distribution might explain, at least in part, the association of
NOD1, but not NOD2, with sarcoidosis susceptibility especially
when systemic organs other than lymphoid tissues are involved.
Functional studies demonstrated similar levels of activity
between the wild-type and mutant NOD1 under conditions with
comparable expression levels, leading us to conclude that
impaired response of the NOD1 variant to P. acnes is due to
reduced expression rather than reduced intrinsic activity of the
NOD1 mutant protein. Our conclusion suggests that the E266K
substitution reduces the stability of NOD1 protein.
Impaired function of NOD2 is associated with Crohn's
disease whereas increased constitutive activity of NOD2 causes
Blau syndrome [30]. Although the mechanism by which
impaired NF-κB activation associated with NOD2 mutations
leads to Crohn's disease remains poorly understood, it has been
suggested that loss of production of antimicrobial molecules
such as alpha-defensins may impair the local response to control
bacterial infection thereby inducing NF-κB overexpression via
NOD2-independent pathways and aberrant inflammation at
intestinal sites [31,32,33]. A similar mechanism may link the
E266K change in NOD1 to sarcoidosis, although the suspected
causative agents of the two diseases are different [34].
NOD1 has recently been reported to be a critical regulator of
beta-defensin-2 during Helicobacter pylori infection [35]. It is
possible that impaired expression of beta-defensin-2 through
796-A NOD1 due to reduced ability to induce NF-κB enables
P. acnes to survive and persist intracellularly, leading to the
pathogenesis of sarcoidosis.
Haplotype frequencies for the E266K-NOD1variant were 0.42
and 0.43 in the disease controls and healthy controls, respectively,
with no significant difference from the value (0.45) obtained from
the NCBI database (rs2075820) where 1228 Japanese subjects
were examined. Although the frequency of the E266K-NOD1
variant was increased significantly in sarcoidosis patients
(P=0.046) even compared with the NCBI SNP database, our
data suggest that in addition to NOD1, other genetic or
environmental factors contribute to the development of sarcoi-
dosis. Similarly, in Crohn's disease, only a subset of patients with
NOD2-associated mutations develop the disease [36].
In conclusion, our data indicate that NOD1 polymorphisms
with haplotypic combinations are important determinants of
sarcoidosis susceptibility. This suggests that altered recognition
of intracellular P. acnes may be one of the key events in the
pathogenesis of sarcoidosis.References
[1] T. Niimi, H. Tomita, S. Sato, H. Kawaguchi, K. Akita, H. Maeda, Y.
Sugiura, R. Ueda, Vitamin D receptor gene polymorphism in patients with
sarcoidosis, Am. J. Respir. Crit. Care Med. 160 (1999) 1107–1109.
800 T. Tanabe et al. / Biochimica et Biophysica Acta 1762 (2006) 794–801[2] M. Petrek, J. Drabek, V. Kolek, J. Zlamal, K.I. Welsh, M. Bunce, E. Weigl,
R. Du Bois, CC chemokine receptor gene polymorphisms in Czech
patients with pulmonary sarcoidosis, Am. J. Respir. Crit. Care Med. 162
(2000) 1000–1003.
[3] T. Takada, E. Suzuki, T. Ishida, H. Moriyama, H. Ooi, T. Hasegawa, H.
Tsukuda, F. Gejyo, Polymorphism in RANTES chemokine promoter
affects extent of sarcoidosis in a Japanese population, Tissue Antigens 58
(2001) 293–298.
[4] E. Yamaguchi, A. Itoh, N. Hizawa, Y. Kawakami, The gene polymorph-
ism of tumor necrosis factor-beta, but not that of tumor necrosis factor-
alpha, is associated with the prognosis of sarcoidosis, Chest 119 (2001)
753–761.
[5] T. Takada, E. Suzuki, K. Morohashi, F. Gejyo, Association of single
nucleotide polymorphisms in the IL-18 gene with sarcoidosis in a Japanese
population, Tissue Antigens 60 (2002) 36–42.
[6] I. Ishige, Y. Usui, T. Takemura, Y. Eishi, Quantitative PCR of
mycobacterial and propionibacterial DNA in lymph nodes of Japanese
patients with sarcoidosis, Lancet 354 (1999) 120–123.
[7] Y. Eishi, M. Suga, I. Ishige, D. Kobayashi, T. Yamada, T. Takemura, T.
Takizawa, M. Koike, S. Kudoh, U. Costabel, J. Guzman, G. Rizzato, M.
Gambacorta, R. du Bois, A.G. Nicholson, O.P. Sharma, M. Ando,
Quantitative analysis of mycobacterial and propionibacterial DNA in
lymph nodes of Japanese and European patients with sarcoidosis, J. Clin.
Microbiol. 40 (2002) 198–204.
[8] T. Yamada, Y. Eishi, S. Ikeda, I. Ishige, T. Suzuki, T. Takemura, T.
Takizawa, M. Koike, In situ localization of Propionibacterium acnes DNA
in lymph nodes from sarcoidosis patients by signal amplification with
catalysed reporter deposition, J. Pathol. 198 (2002) 541–547.
[9] N. Inohara, T. Koseki, L. del Peso, Y. Hu, C. Yee, S. Chen, R. Carrio, J.
Merino, D. Liu, J. Ni, G. Nunez, Nod1, an Apaf-1-like activator of caspase-
9 and nuclear factor-kappaB, J. Biol. Chem. 274 (1999) 14560–14567.
[10] M. Chamaillard, M. Hashimoto, Y. Horie, J. Masumoto, S. Qiu, L. Saab, Y.
Ogura, A. Kawasaki, K. Fukase, S. Kusumoto, M.A. Valvano, S.J. Foster,
T.W. Mak, G. Nunez, N. Inohara, An essential role for NOD1 in host
recognition of bacterial peptidoglycan containing diaminopimelic acid,
Nat. Immunol. 4 (2003) 702–707.
[11] N. Inohara, Y. Ogura, F.F. Chen, A. Muto, G. Nunez, Human Nod1 confers
responsiveness to bacterial lipopolysaccharides, J. Biol. Chem. 276 (2001)
2551–2554.
[12] P. Hysi, M. Kabesch, M.F. Moffatt, M. Schedel, D. Carr, Y. Zhang, B.
Boardman, E. von Mutius, S.K. Weiland, W. Leupold, C. Fritzsch, N.
Klopp, A.W. Musk, A. James, G. Nunez, N. Inohara, W.O. Cookson,
NOD1 variation, immunoglobulin E and asthma, Hum. Mol. Genet. 14
(2005) 935–941.
[13] D.P. McGovern, P. Hysi, T. Ahmad, D.A. van Heel, M.F. Moffatt, A.
Carey, W.O. Cookson, D.P. Jewell, Association between a complex
insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to
inflammatory bowel disease, Hum. Mol. Genet. 14 (2005) 1245–1250.
[14] Y. Ogura, D.K. Bonen, N. Inohara, D.L. Nicolae, F.F. Chen, R. Ramos,
H. Britton, T. Moran, R. Karaliuskas, R.H. Duerr, J.P. Achkar, S.R.
Brant, T.M. Bayless, B.S. Kirschner, S.B. Hanauer, G. Nunez, J.H. Cho,
A frameshift mutation in NOD2 associated with susceptibility to
Crohn's disease, Nature 411 (2001) 603–606.
[15] C. Miceli-Richard, S. Lesage, M. Rybojad, A.M. Prieur, S. Manouvrier-
Hanu, R. Hafner, M. Chamaillard, H. Zouali, G. Thomas, J.P. Hugot,
CARD15 mutations in Blau syndrome, Nat. Genet. 29 (2001) 19–20.
[16] N. Kanazawa, I. Okafuji, N. Kambe, R. Nishikomori, M. Nakata-Hizume,
S. Nagai, A. Fuji, T. Yuasa, A. Manki, Y. Sakurai, M. Nakajima, H.
Kobayashi, I. Fujiwara, H. Tsutsumi, A. Utani, C. Nishigori, T. Heike, T.
Nakahata, Y. Miyachi, Early-onset sarcoidosis and CARD15 mutations
with constitutive nuclear factor-kappaB activation: common genetic
etiology with Blau syndrome, Blood 105 (2005) 1195–1197.
[17] M. Schurmann, R. Valentonyte, J. Hampe, J. Muller-Quernheim, E.
Schwinger, S. Schreiber, CARD15 gene mutations in sarcoidosis, Eur.
Respir. J. 22 (2003) 748–754.
[18] H. Zouali, S. Lesage, F. Merlin, J.P. Cezard, J.F. Colombel, J. Belaiche,
S. Almer, C. Tysk, C. O'Morain, M. Gassull, S. Christensen, Y. Finkel,
R. Modigliani, C. Gower-Rousseau, J. Macry, M. Chamaillard, G.Thomas, J.P. Hugot, EPWG group, EPIMAD group, CARD4/NOD1 is
not involved in inflammatory bowel disease, Gut 52 (2003) 71–74.
[19] Y. Ogura, N. Inohara, A. Benito, F.F. Chen, S. Yamaoka, G. Nunez, Nod2,
a Nod1/Apaf-1 family member that is restricted to monocytes and activates
NF-kappaB, J. Biol. Chem. 276 (2001) 4812–4818.
[20] Y. Ebe, S. Ikushima, T. Yamaguchi, K. Kohno, A. Azuma, K. Sato, I.
Ishige, Y. Usui, T. Takemura, Y. Eishi, Proliferative response of peripheral
blood mononuclear cells and levels of antibody to recombinant protein
from Propionibacterium acnes DNA expression library in Japanese
patients with sarcoidosis, Sarcoidosis Vasc. Diffuse Lung Dis. 17 (2000)
256–265.
[21] J. Minami, Y. Eishi, Y. Ishige, I. Kobayashi, I. Ishige, D. Kobayashi, N.
Ando, K. Uchida, S. Ikeda, N. Sorimachi, H. Karasuyama, T. Takemura, T.
Takizawa, M. Koike, Pulmonary granulomas caused experimentally in
mice by a recombinant trigger-factor protein of Propionibacterium acnes,
J. Med. Dent. Sci. 50 (2003) 265–274.
[22] I. Ishige, Y. Eishi, T. Takemura, I. Kobayashi, K. Nakata, I. Tanaka, S.
Nagaoka, K. Iwai, K. Watanabe, T. Takizawa, M. Koike, Propionibac-
terium acnes is the most common bacterium commensal in peripheral lung
tissue and mediastinal lymph nodes from subjects without sarcoidosis,
Sarcoidosis Vasc. Diffuse Lung Dis. 22 (2005) 33–42.
[23] T. Nishiwaki, H. Yoneyama, Y. Eishi, N. Matsuo, K. Tatsumi, H.
Kimura, T. Kuriyama, K. Matsushima, Indigenous pulmonary Propio-
nibacterium acnes primes the host in the development of sarcoid-like
pulmonary granulomatosis in mice, Am. J. Pathol. 165 (2004)
631–639.
[24] Y. Eishi, I. Ishige, Y. Ishige, T. Yamada, J. Minami, S. Ikeda, M. Koike,
Etiology of sarcoidosis: the role of Propionibacterium acnes, Acta
Histochem. Cytochem. 36 (2003) 15–26.
[25] I. Nagy, A. Pivarcsi, A. Koreck, M. Szell, E. Urban, L. Kemeny, Distinct
strains of Propionibacterium acnes induce selective human beta-defensin-
2 and interleukin-8 expression in human keratinocytes through toll-like
receptors, J. Invest. Dermatol. 124 (2005) 931–938.
[26] C. Kalis, M. Gumenscheimer, N. Freudenberg, S. Tchaptchet, G. Fejer, A.
Heit, S. Akira, C. Galanos, M.A. Freudenberg, Requirement for TLR9 in
the immunomodulatory activity of Propionibacterium acnes, J. Immunol.
174 (2005) 4295–4300.
[27] U. Jappe, R. Boit, M.D. Farrar, E. Ingham, J. Sandoe, K.T. Holland,
Evidence for diversity within Propionibacterium acnes: a comparison of
the T-cell stimulatory activity of isolates from inflammatory acne,
endocarditis and the laboratory, J. Eur. Acad. Dermatol. Venereol. 18
(2004) 450–454.
[28] B. Wang, S. Li, P.J. Southern, P.P. Cleary, Streptococcal modulation of
cellular invasion via TGF-β1 signaling, Proc. Natl. Acad. Sci. U. S. A. 103
(2006) 2380–2385.
[29] Y. Eishi, Propionibacterium acnes as a cause of sarcoidosis, in: R.P.
Baughman (Ed.), Sarcoidosis, Marcel Dekker, Inc., New York, 2006,
pp. 277–296.
[30] T. Tanabe, M. Chamaillard, Y. Ogura, L. Zhu, S. Qiu, J. Masumoto, P.
Ghosh, A. Moran, M.M. Predergast, G. Tromp, C.J. Williams, N.
Inohara, G. Nunez, Regulatory regions and critical residues of NOD2
involved in muramyl dipeptide recognition, EMBO J. 23 (2004)
1587–1597.
[31] K.S. Kobayashi, M. Chamaillard, Y. Ogura, O. Henegariu, N. Inohara, G.
Nunez, RA. Flavell, Nod2-dependent regulation of innate and adaptive
immunity in the intestinal tract, Science 307 (2005) 731–734.
[32] J. Wehkamp, J. Harder, M. Weichenthal, M. Schwab, E. Schäffeler, M.
Schlee, K.R. Herrlinger, A. Stallmach, F. Noack, P. Fritz, J.M. Schröder,
C.L. Bevins, K. Fellermann, E.F. Stange, NOD2 (CARD15) mutations
in Crohn's disease are associated with diminished mucosal α-defensin
expression, Gut 53 (2004) 1658–1664.
[33] J. Wehkamp, N.H. Salzman, E. Porter, S. Nuding, M. Weichenthal, R.E.
Petras, B. Shen, E. Schaeffeler, M. Schwab, R. Linzmeier, R.W. Feathers,
H. Chu, H. Lima Jr., K. Fellermann, T. Ganz, E.F. Stange, C.L. Bevins,
Reduced Paneth cell α-defensins in ileal Crohn's disease, Proc. Natl. Acad.
Sci. U. S. A. 13 (2005) 18129–18134.
[34] F. Autschbach, S. Eisold, U. Hinz, S. Zinser, M. Linnebacher, T. Giese, T.
Löffler, M.W. Büchler, J. Schmidt, High prevalence of Mycobacterium
801T. Tanabe et al. / Biochimica et Biophysica Acta 1762 (2006) 794–801avium subspecies paratuberculosis IS900 DNA in gut tissue from
individuals with Crohn's disease, Gut 54 (2005) 944–949.
[35] P.K. Boughan, R.H. Argent, M. Body-Malape, Jong-Hwan Park, K.E.
Ewings, A.G. Bowie, S.J. Ong, S.J. Cook, O.E. Sorensen, B.A. Manzo, N.
Inohara, N.J. Klein, G. Nuñez, J.C. Atherton, M. Bajaj-Elliott, Nucleotide-binding oligomerization domain-1 and epidermal growth factor receptor,
J. Biol. Chem. 281 (2006) 11637–11648.
[36] K. Linde, P.P. Boor, J.J. Houwing-Duistermaat, E.J. Kuipers, J.H. Wilson, F.W.
de Rooij, CARD15 and Crohn's disease: healthy homozygous carriers of the
3020insC frameshift mutation, Am. J. Gastroenterol. 98 (2003) 613–617.
